Abstract

Factor Va, the essential cofactor for prothrombinase, is phosphorylated on the acidic COOH terminus of the heavy chain of the cofactor, at Ser692, by a platelet membrane-associated casein kinase II (CKII). Consistent with this observation, phosphorylation of the factor Va heavy chain by the platelet kinase was inhibited by heparin. The membrane-associated platelet CKII kinase was partially purified using heparin-agarose, phosphocellulose, and ion exchange chromatography. CKII antigen was monitored using a polyclonal antibody to the alpha-subunit, and kinase activity in the various fractions was confirmed using human factor Va as a substrate. Immunoblotting experiments using polyclonal antibodies raised against synthetic peptides mimicking a portion of the deduced amino acid sequence of the alpha-, alpha'-, and beta-subunits of human CKII demonstrated the coexistence of both alpha- and alpha'-subunits in platelets and suggested that the platelet CKII kinase may exist in part as an alpha alpha'beta2 complex. It is also possible that there are two distinct populations of CKII in platelets, one that is alphaalpha/betabeta and one that is alpha'alpha'/betabeta. In the presence of the purified platelet-derived CKII, human factor Va incorporates between 0.8 and 1.3 mol of phosphate/mol of factor Va depending on the concentration of the beta-subunit in the kinase preparation. A peptide mimicking the sequence 687-705 of the human factor V molecule incorporates radioactivity in the presence of purified CKII and inhibits factor Va heavy chain phosphorylation by the platelet CKII. In contrast, a peptide with an alanine instead of a serine at position 692 neither incorporates phosphate nor inhibits factor Va phosphorylation by the platelet CKII. Human factor Va is inactivated by activated protein C following three cleavages of the heavy chain at Arg506, Arg306, and Arg679. Cleavage at Arg506 is necessary for efficient exposure of the inactivating cleavage site at Arg306. The phosphorylated cofactor has increased susceptibility to inactivation by activated protein C, since phosphorylated factor Va was found to be inactivated approximately 3-fold faster than its native counterpart. Acceleration of the inactivation process of the phosphorylated cofactor occurs because of acceleration of the rate of cleavage at Arg506. These data suggest a critical role for factor Va phosphorylation on the surface of platelets in regulating cofactor activity.

Highlights

  • Most of the factor V is found in the plasma, where it circulates at a concentration of 7 ␮g/ml (20 nM)

  • Following cleavage of phosphorylated human factor Va by activated protein C (APC) at Arg506, radioactivity was found in the COOH-terminal fragment of the heavy chain

  • Since phosphoserine was the only phosphoamino acid detected (21, 22), it was concluded that amino acid sequence 680 –709 of human factor Va heavy chain must contain a serine that is phosphorylated by the platelet casein kinase II (CKII)

Read more

Summary

Introduction

Most of the factor V is found in the plasma, where it circulates at a concentration of 7 ␮g/ml (20 nM). It has been repeatedly shown that human platelets contain a protein possessing casein kinase II (CKII) activity (15–19). It has been proposed that the plasma protein kinases may originate from platelets, since no kinase activity seems to be present in human blood plasma. Recent data have demonstrated that bovine coagulation factor Va incorporates 32PO4 into the heavy chain in the presence of [␥-32P]ATP and a platelet kinase contained in the activated platelet soluble fraction (APSF) following activation of human platelets by ␣-thrombin (21) and that human plasma factor Va is stoichiometrically phosphorylated on both the heavy and light chains in the presence of whole platelets (platelet membranes plus APSF) (22).

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.